Fig. 1.
64Cu-LLP2A PET/CT in bleomycin-induced lung injury. Representative axial CT, PET, and co-registered PET/CT (A) of control versus bleomycin-treated mice acquired ~ 4 h after 64Cu-LLP2A administration demonstrate significant increases in the tracer uptake during different stages of fibrotic lung injury. The specificity of tracer uptake is confirmed by blocking 64Cu-LLP2A uptake, despite the presence of CT evidence of lung injury, by co-injection of excess non-labeled LLP2A (right panels in A). PET-derived quantification, measured as %ID/mLmean (B) and %ID/mLmax (C), confirms significant increases in 64Cu-LLP2A uptake throughout different stages of the progression of bleomycin-induced lung injury as well its near-complete blockade by co-injection of non-labeled LLP2A. N = 14 (control), 22 (1-week), 10 (2-week), 8 (4-week), and 4 (2-week blocked). PBS = phosphate-buffered saline